Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti Ú 77,22 ⏠(-1,96%). La mediana Ú 86,41 ⏠(+9,71%).
| Acquista |
Â
9 |
| Mantieni |
Â
2 |
| Vendi |
Â
1 |
Discussioni nella community
- 3M Spin-Off von Solventum
Gestern wurde der Spin-Off der Healthcare Sparte unter Solventum in den Depots durchgefĂŒhrt. Man hat fĂŒr jede vierte 3M Aktie eine Solventum Aktie erhalten. Komischerweise steht nun meine Position inâŠ
Puncher I in Schnack
0 6 - Korrektur der automatisch erstellten AktivitÀt des Spin-OffŽs bei 3M
Hallo zusammen, der Spin-Off von 3M wurde ja automatiasch in die AktivitĂ€ten eingetragen. Hierzu mal ein dickes Lob fĂŒr diese neue Funktion. Leider passt die nicht ganz bei mir - 3M bzw. TradeâŠ
K Kai V in Schnack
0 14 - SpinOff 3M
Hallo, hier bei Parqet, ist ja der SpinOff schon eingetragen. Bei meinem Brocker Trade Republic ist dieser noch nicht abgeschlossen. Gibt es schon jemanden von euch, bei dem die Werte (StĂŒckzahl,âŠ
Maik S. II in Schnack 0 4 - Hallo, nach einem Spin-off bei 3M und A.P. Moller-Mearsk B werden mir falsche Einstiegskurse angezeigt. Ich kann das nicht korrigieren. Pflege ich die PDF Datei neu ein, kommen weiter Automatisch die falschen Einstiegskurse. Gibt es schon ein Lösung?
PN Parqet Nutzer IV in Schnack
1 27 Tradotto (originale in tedesco)
NovitĂ : Registrazione automatica degli Spin-OffCaro Community, forse alcuni di voi azionisti di 3M l'hanno giĂ scoperto nel vostro portafoglio: la registrazione automatica degli Spin-Off Ăš ora live! Cosa significa per voi? Da ora in poi, tuttiâŠ
Lisa I in Neues vom Parqet Team 37 51
Notizie Vai al feed delle notizie
Solventum sharpens medtech strategy and plans spin-off of HIS division
Solventum announced at the Wells Fargo healthcare conference that it will focus more on medical technology and spin off its Healthcare Information Services (HIS) unit, with options including sale, spin-off or partnership. The company raised its forecast for organic growth in 2026 to 2.5â3.0% but expects a near-term margin dilution of around 400 basis points from the HIS separation. MedSurg and dental (over 80% of the business) remain the main growth drivers; about 20 new products are planned by Q1 2028, with a target of 4â5% organic growth for 2028 (ex-HIS). » Altro su de.investing.com
Solventum reaches 52-week high at $88.21
Solventum shares rose to a new 52-week high of $88.21, gaining nearly 11% on the week. The healthâtechnology company has a market capitalization of $14.92 billion and is up about 20.6% year to date. Solventum beat expectations in Q1 of fiscal 2026 with EPS of $1.48 (forecast $1.34) on organic revenue growth of 2.1%. Analysts rated the stock positively; the P/E ratio is around 9.3, which the fairâvalue estimate signals as a slight overvaluation. » Altro su de.investing.com
UBS upgrade drives Solventum stock sharply higher
UBS upgraded Solventum from âNeutralâ to âBuyâ and set a $95 price target, implying roughly 18% upside. The stock rose 7.6% in morning trading and hit a daily high of $87.19, close to its 52-week high of $88.20. Earlier positive analyst notes from BTIG and KeyBanc, along with four consecutive quarters of EPS beats, underpin expectations for a strong Q2 report on Aug. 5. The rally was stock-specific while broad US indices were mostly weaker. » Altro su de.investing.com
Trian demands cost cuts, divestments and buybacks at Solventum after spin-off
Trian Fund Management has disclosed just under a 5% stake in Solventum and, in an open letter, demanded three value-boosting measures: reduce overhead to 3M-levels, sell non-core divisions including Health Information Systems, and prioritize share buybacks. Trian criticizes that the market capitalization of around $12 billion is far below the $25 billion expected at the spin-off and sees about $13 billion of shareholder value destroyed. The investor also condemns high executive compensation since the spin-off without corresponding returns for shareholders and says it will communicate with other large shareholders and may adjust its position. » Altro su de.investing.com
Trian demands cost cuts, sale of non-core businesses and share buybacks at Solventum
Trian Fund Management has disclosed an almost 5% stake in Solventum and, in an open letter, is calling for operational changes including reducing overhead to 3M levels, selling non-core divisions such as Health Information Systems, and prioritizing share buybacks. Trian criticizes Solventum for not delivering returns to shareholders since the spin-off and sees a dilution of company value compared with earlier analyst estimates. Solventum is trading near its 52-week low but remains profitable with earnings of $8.88 per share and a P/E ratio of 7.78. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 1,72Â Mld | 3,66% |
| Utile lordo | 937,59Â Mln | 6,52% |
| Utile netto | -10,59Â Mln | 100,98% |
| EBITDA | 50,32Â Mln | 96,57% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 13,77 Mld ⏠|
Numero di azioni | 169,96Â Mln |
Massimo/minimo a 52 settimane | 85,65 ⏠- 56,74 ⏠|
| Dividendi | No |
Beta | 0,75 |
Rapporto P/E | 100,09 |
Rapporto PEG | -1,11 |
Rapporto P/B | 3,17 |
Rapporto P/S | 1,85 |
Profilo aziendale
Solventum Corporation, un'azienda sanitaria, si occupa dello sviluppo, della produzione e della commercializzazione di un portafoglio di soluzioni per rispondere alle esigenze critiche di clienti e pazienti. Opera attraverso quattro segmenti: Medsurg, Dental Solutions, Health Information Systems e Purification and Filtration. Il segmento Medsurg fornisce soluzioni tra cui la cura avanzata delle ferite, la gestione dei siti I.V., la garanzia di sterilizzazione, la gestione della temperatura, forniture chirurgiche, stetoscopi ed elettrodi medicali. Il segmento Dental Solutions offre una suite completa di prodotti per odontoiatria e ortodonzia, tra cui bracket, allineatori, cementi restaurativi e agenti adesivi. Health Information Systems fornisce soluzioni software, tra cui sistemi assistiti da computer, documentazione medica, fatturazione diretta e automazione della codifica, metodologie di classificazione, piattaforme di riconoscimento vocale e di visualizzazione dei dati. Il segmento Purification and Filtration fornisce tecnologie di purificazione e filtrazione, tra cui filtri, purificatori, cartucce e membrane. La societĂ Ăš stata costituita nel 2023 ed ha sede a Saint Paul, Minnesota.
| Nome | Solventum |
| CEO | Bryan C. Hanson |
| Sede centrale | Eagan,
mn Stati Uniti |
| Sito web | |
| Settore | SanitĂ |
| Industria | Attrezzature e forniture sanitarie |
| Quotazione in borsa | 21/07/2014 |
| Dipendenti | 20.584 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | SOLV |
Frankfurt | KB7.F |
DĂŒsseldorf | KB7.DU |
MĂŒnchen | KB7.MU |